Omics approaches, including genomics, transcriptomics, proteomics, epigenomics, microbiomics, and metabolomics, generate large data sets. Once they have been used to address initial study aims, these large data sets are extremely valuable to the greater research community for ancillary investigations. Repurposing available omics data sets provides data to address research questions, generate and test hypotheses, replicate findings, and conduct mega-analyses. Many well-characterized, longitudinal, epidemiological studies collected extensive phenotype data related to symptom occurrence and severity. While the main phenotype of interest for many of these studies was often not symptom related, these data were collected to better understand the primary phenotype of interest. A search for symptom data (i.e., cognitive impairment, fatigue, gastrointestinal distress/nausea, sleep, and pain) in the database of genotypes and phenotypes (dbGaP) revealed many studies that collected symptom and omics data. There is thus a real possibility for nurse scientists to be able to look at symptom data over time from thousands of individuals and use omics data to identify key biological underpinnings that account for the development and severity of symptoms without recruiting participants or generating any new data. The purpose of this article is to introduce the reader to resources that provide omics data to the research community for repurposing, provide guidance on using these databases, and encourage the use of these data to move symptom science forward.
Omics research approaches generate large data sets, a type of ''big data'' that is used to test biological pathways of interest as well as perform nonparametric evaluations that identify what regions of the genome, genes, or biological pathways are related to the phenotype of interest. The practice of making omics data available to the research community for repurposing is gaining momentum, and many funding agencies mandate the sharing of these data. An example is the National Institutes of Health (NIH) Genomic Data Sharing Policy, which promotes responsible sharing of any large-scale genomic data (genomic, transcriptomic, epigenomic, etc.) generated with NIH funding (https://gds.nih.gov). Omics data from large, longitudinal, well-characterized cohorts, such as the Framingham Heart Study, the Nurses' Health Study, and the Jackson Heart Study, are available for repurposing by the research community for further scientific inquiry. Repurposing available omics data sets can provide data to address research questions, generate or test specific hypotheses, and conduct mega-analyses, all of which can be used to aid in directing a program of research.
The National Institute of Nursing Research (NINR) is committed to genomic nursing research (Tully & Grady, 2015) , and based on The Blueprint for Genomic Nursing Science (Calzone et al., 2013) and the NINR Four Key Research Themes (NINR, 2016) , there are many instances where repurposing existing omics data could be used to address NINR's mission. For example, one research theme that would benefit from repurposing existing omics data is symptom science and the promotion of precision health strategies. Many of the wellcharacterized, longitudinal, epidemiological studies that have made their omics data available collected extensive phenotype data related to symptom occurrence and severity, endogenous and exogenous exposures, and comorbidities in addition to extensive demographic data. The main phenotype of interest for many of these studies was often not symptom related, but data on symptoms were collected to better understand the primary phenotype of interest. Indeed, the symptom-related data were often included to address potential confounding variables. These data could be instrumental in developing precision strategies for the prevention and treatment of symptoms.
An additional area that is receiving a considerable amount of effort is the linking of electronic health records to omics data for research purposes. Examples of these initiatives include the Electronic Medical Records and Genomics (n * 18,600) and the Resource of Genetic Epidemiology Research on Aging (n * 78,400) projects. Nurse scientists are ideal investigators for these initiatives and should be at the front line of efforts that leverage big data-related opportunities to improve patient care (Brennan & Bakken, 2015) .
The purpose of this article is 3-fold: (1) to introduce the reader to resources that provide omics data to the research community for repurposing, (2) to provide guidance on the utility of these resources, and (3) to encourage the use of these available data sources to move symptom science forward.
Existing Omics Data Available to the Research Community
The suffix omics, when used in terms such as genomics, transcriptomics, proteomics, epigenomics, microbiomics, and metabolomics, indicates looking at the totality of data for the chosen approach. The term genomics, therefore, refers to characterizing the DNA variability in not one gene, but all genes across the genome. The term transcriptomics refers to characterizing not one RNA transcript, but all RNA transcripts from a cell, tissue, or organism.
The Human Genome Project (HGP) was the first big data omics project in which the resulting data were made readily available to the larger scientific community (National Human Genome Research Institute, 2016) . The sequence of the 3 billion DNA bases in the human genome revealed more than a decade ago through the HGP is available through a variety of integrated databases. The pace of the collecting of omic-type data is showing no sign of slowing down as the research community increasingly recognize the promise of omics. Moreover, the techniques for collecting these data are rapidly improving. For example, sequencing the human genome for the HGP took over a decade, while next generation sequencing can sequence a human genome in days and at a fraction of the cost (Conley et al., 2013) . Table 1 provides information about selected databases and resources available to the research community for repurposing of omics data. These databases are continuously being updated and are curated by reliable agencies; therefore, they represent a means to stay up-to-date on available resources. Additionally, we direct readers to the 2016 Database Issue of Nucleic Acids Research (Rigden, Fernandez-Suarez, & Galperin, 2016) , which provides an overview of a variety of omics databases. This issue is freely available online at http://nar.oxfordjournals. org. A more thorough list of databases available online can be found at http://oxfordjournals.org/nar/database/c/
Guidance on Using Omics Databases
Conceptualizing how to use the data available through omics databases to address symptom science starts by identifying the problem. For example, we do not fully understand the biological underpinnings of fatigue or variability in those who experience fatigue. This knowledge could provide the evidence base to guide investigations into the development of new interventions and aid in progress toward precision health care for fatigue. Two possible solutions to address this problem are as follows: (1) recruit, phenotype, and collect omics data from biospecimens for thousands of subjects and conduct a nonparametric analysis of these data to determine what genes and biological pathways are involved in fatigue or (2) obtain already existing omics and phenotype data from thousands of subjects through omics databases and conduct a nonparametric analysis of these data to determine what genes and biological pathways are involved in fatigue. Both of these potential solutions would result in biologically guided hypothesis generation and establish the preliminary data to support further investigation; however, the second solution efficiently addresses the study question using existing resources. In addition to its utility for hypothesis generation, as in the example above, data from omics databases can be used for hypothesis testing, including analysis of targeted candidate biological pathways.
These omics databases are catalogs of studies that include key information about the studies, themselves, and the omics data available. Users can conduct searches using key words such as the phenotype of interest (e.g., depression, anxiety, pain, or fatigue) or may search the databases for specific studies or cohorts. Using the database of genotypes and phenotypes (dbGaP) as an example, a search for the key word fatigue would return not only studies that collected fatiguespecific data but also those that mention fatigue in other ways that may not be as relevant, such as if a subject stopped data collection due to fatigue. Users can limit their searches in dbGaP by clicking on the ''limit'' hyperlink and choosing from a long list of fields to search, including, for example, ''variable.'' dbGaP also has an advanced search function that allows users to build a search using Boolean terms like and, or, and not to build specific searches across multiple fields. The dbGaP handbook provides further instruction on optimizing searches within dbGaP (www.ncbi.nlm.nih.gov/books/ NBK154410).
Access to some of these databases is restricted and requires an application outlining the intended use, a data sharing agreement, and in some cases approval by a local institutional review board. For example, as part of the application process to gain access to data in dbGaP, database administrators conduct a review that evaluates the proposed research and terms of the original consent given by the research subjects. The procedure to secure access to dbGaP data can be found at https://dbgap.ncbi.nlm. nih.gov/aa/wga.cgi?login¼&page¼login. In addition, dbGaP recently opened access to a collection of studies with data appropriate for general research use that researchers can use for secondary data analyses without limitation. See the NCBI dbGaP collection's website (http://www.ncbi.nlm.nih.gov/proj ects/gap/cgi-bin/collection.cgi?study_id¼phs000688.v1.p1)
for more information about these data. The larger dbGaP database houses information on all studies available for data repurposing (www.ncbi.nlm.nih.gov/gap). www.wtccc.org.uk The primary purpose of the WTCCC is to accelerate efforts to identify genome sequence variants influencing major causes of human morbidity and mortality through implementation and analysis of largescale GWAS. Additional objectives include the development and validation of informatics and analytical solutions appropriate to the scale and nature of the project as well as use of the data generated to answer important methodological and biological questions relevant to association studies in general and in the UK in particular (e.g., issues of population substructure). The consortium anticipates that data generated from the project will be used by others, with potential applications including developing new analytical methods, understanding patterns of polymorphisms, and guiding selection of markers to map genes involved in specific diseases. The initial search results in dbGaP are presented in a tabular format that lists study name, whether the data are currently available or embargoed (along with release date), number of participants with data available through dbGaP, type of study (case-control, family based, cohort, longitudinal, etc.) , and the omics data collection platform(s) used. The study name is clickable and links you to more detailed information about the study including descriptions of the study, study design, phenotyping, and omics data collection efforts; inclusion and exclusion criteria for recruitment; how and when the biological samples were collected; and information about the study history. This information includes selected publications related to the study, identification (requestor name, affiliation, project title, and approval date) of researchers already granted access to the data, and names and affiliations of the investigators involved in the original study. These initial search results are a great starting place for learning more about what data are available for your phenotype of interest.
Exemplar Database Searches
To see how well represented symptom-related data might be in publicly available omics databases, we conducted some exemplary searches using mostly dbGaP and focused primarily on DNA variability, gene expression, and DNA methylation data. These searches reflect a cross-sectional snapshot of extremely dynamic databases to which data and information are frequently added. Therefore, readers interested in these symptoms are encouraged to conduct up-to-date searches of these databases. We conducted searches related to the following phenotypes: cognitive impairment, fatigue, gastrointestinal (GI) distress/nausea, sleep, and pain. We searched specifically for studies that included one or more of these symptoms as a study variable measured in conjunction with a variety of omics data. Table 2 details the steps we took to conduct these searches.
Through our search, we found that cognitive impairment was measured as a variable in 19 studies with omics data available, fatigue in 13 studies, GI distress/nausea in 16 studies, sleep in 30 studies, and pain in 29 studies. Some of the studies focused on specific patient populations, such as those with diabetes, cardiovascular disease, chronic obstructive pulmonary disease, stroke, and a variety of mental health and neurological disorders. Fatigue was the only symptom for which study subjects seemed to be limited to the adult population; studies in children were available for the other symptoms. One issue that became apparent through the course of our search was that phenotypic data were not collected in a consistent manner between studies. Of particular interest are the studies that collected omics data and data on these symptoms over time in healthy, community-dwelling individuals, such as the Jackson Heart Study (n * 3,300), the Women's Health Initiative (n * 64,000), the Cardiovascular Health Study (n * 5,200), and the Framingham Cohort studies (n * 15,000). Table 3 presents more information about the search results, including instruments and measurements the studies used to collect symptom phenotypes and demographic data for the study populations.
Common Challenges With and Recommendations for Using Shared Omics Data
There are many challenges associated with using shared omics data that can impact the utility and interpretation of the data. Common examples include the following: data in the database represent only a subset of subjects from the study; lack of indepth information on how symptom phenotypes were collected and adjudicated; and important methodological information about the study, for example, recruitment schema, is not available through the database.
It is not uncommon for data from a subset of available subjects from a cohort to be deposited into a data sharing database. Investigators may only make data available through omics database requests from subjects who agreed to release of their data to other investigators not affiliated with the original project or the original investigators. This means that, for some studies, a substantial number of subjects' omics data cannot be made available through the database. However, subjects may have consented to sharing data in ways other than through publicly available databases. For example, they may have consented to sharing of data with direct collaborators of the original investigators. Therefore, collaborating directly with the study investigators for data access may result in access to more subjects, leading to increased power and potentially reducing issues around selection bias.
A lack of understanding of how symptom phenotype data were generated in a study can impact authors' abilities to effectively combine phenotype data for mega-analyses and to assess the rigor and robustness of the data. Many of the studies that have data deposited into the databases have websites established for those studies, for example, the Cardiovascular Health Study (CHS) at https://chs-nhlbi.org. The study websites frequently provide better insight into the phenotypes collected than the data sharing databases and often have the data collection instruments available for review and provide the standardized protocols for data collection. Additionally, the study website may provide information about phenotypes not deposited into the database. For example, investigators collected data on quality of life, social support, and stressful life events in the CHS, but these phenotypes are not mentioned in dbGaP. The study website will also often have information about approved ancillary studies, including those being conducted by the study investigators that would not be represented in databases like dbGaP; thus, researchers can confirm that what they want to do has not been proposed already.
Making decisions about what data to request access to and then interpreting findings from the data analyses require indepth information about the methodologies investigators used To learn the details of the study Viewed the description of the study, the variables collected, study document provided, data sets, and molecular data 3. Clicked on the ''Variables'' tab To search through the variables to determine if and how fatigue was measured 5 folders containing the variables collected as part of the study became available for searching 4. Clicked on ''Phenotype-Details'' folder To discover how fatigue was measured 2 subfolders containing the variables collected as part of the study available for searching 5. Clicked on ''Medical History'' subfolder To discover how fatigue was measured 14 subfolders containing data from study questionnaires available for searching 6. Clicked on ''Short-Form (SF12)'' subfolder To discover how fatigue was measured 2 subfolders containing the variables from the SF12 available for searching 7. Clicked on ''Physiological Measurements and Observations'' subfolder in the original study, including recruitment strategies and inclusion and exclusion criteria. How subjects were recruited and selected are important considerations when assessing the quality of the original study, determining how appropriate the study data would be for addressing the research questions or hypotheses of another study, and interpreting the findings from a study that utilized the data from the original study. Fortunately, many of the researchers who have made their data available in these databases have published articles about their methodologies; therefore, a thorough literature search can capture this information. Other information that can be extracted from the literature may include the number of subjects in the original study, which can differ significantly from what is available through the databases, how certain types of data were collected, and what has been published so far (to prevent overlap of effort and highlight opportunities for additional inquiry). Pain was the symptom of interest A total of 105 studies were identified; however, a number of the studies were not directly related to pain 2. Conducted an advanced search in dbGaP using pain in the ''variable'' field
To limit search to studies that collected pain as a variable A total of 33 studies were identified 3. Conducted an advanced search in dbGaP using pain in the ''variable description'' field
To limit search to studies that collected pain as a variable A total of 31 studies were identified 4. Conducted an advanced search using pain in the ''variable name'' field
To limit search to studies that collected pain as a variable A total of 8 studies were identified 5. Conducted an advanced search using pain in the ''study name'' field
To limit search to studies that collected pain as a main focus A total of 2 studies were identified 6. Clicked on each study and then clicked through each pain variable to look at details
To make sure that pain was included as a major outcome in the selected studies
Only 29 studies had data available directly related to pain Other challenges associated with using shared omics data include adjudication of omics data, combining omics data collected using multiple data collection platforms, and the ethical and policy-related issues around sharing the data and subsequent findings. These are important issues currently receiving attention in the omics scientific community. The white paper from the National Consortium for Data Science entitled Data to Discovery: Genomes to Health (Ahalt et al., 2014) provides more information related to these challenges.
An additional challenge related to using data available through omics databases is that analyses of data and interpretation of findings, particularly if whole genome data will be analyzed, require specialized statistical and bioinformatics expertise. Although the entire research community faces this issue, it may be especially challenging for nurse scientists who may not have access to the necessary resources or statistical expertise among their network of current collaborators. We encourage scientists embarking on a project involving the access of data through omics databases to seek guidance from potential colleagues at bioinformatics and computational genomics cores, which are found at many universities and medical centers and whose services are often available to collaborators from outside of their university. These cores are charged with facilitating translational research; therefore, they are ideal collaborators for nurse scientists who conceptualize the translational use of these data.
Conclusion
Scientists today have a golden opportunity to address big questions and substantially move symptom science forward by taking advantage of the abundance of phenotype and omics-related data available for the asking. The wealth of data available and the infinite research questions that can be asked with these data are inspiring. Tremendous resources have been invested into the studies that are making their omics data available to the research community. Many of these studies recruited thousands of individuals and families, collected and banked biospecimens, and collected copious amounts of personal and phenotype data (often longitudinally) and a variety of omics data. Nurse scientists are well positioned to repurpose these data to answer new questions and generate and test new hypotheses related to symptoms that the research community has not been yet addressed.
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